56612 Federal Register / Vol. 73, No. 189 / Monday, September 29, 2008 / Notices 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than October 29, 2008. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745), all applicants for 

registration to import a basic class of 

any controlled substance in schedules I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: September 22, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–22873 Filed 9–26–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 24, 2008, 

Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066–1742, made application by letter 

to the Drug Enforcement Administration 

(DEA) as a bulk manufacturer of 

Gamma-Hydroxybutyric acid (2010), a 

basic class of controlled substance listed 

in schedule I. 

The company plans on producing 

sodium oxybate for sale to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 28, 2008. 

Dated: September 22, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–22874 Filed 9–26–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated May 19, 2008 and 

published in the Federal Register on 

May 27, 2008 (73 FR 30418), AMRI 

Rensselaer, Inc., 33 Riverside Avenue, 

Rensselaer, New York 12144, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule I and II: 

Drug Schedule 

Marihuana (7360) .......................... I 

Tetrahydrocannabinols (7370) ...... I 

Amphetamine (1100) ..................... II 

Lisdexamfetamine (1205) .............. II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ...................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ......................... II 

Dextropropoxyphene, bulk (nondosage form) (9273).II 

Oxymorphone (9652) .................... II 

Fentanyl (9801) ............................. II 

The company plans to manufacture 

bulk controlled substances for use in 

product development and for 

distribution to its customers. In 

reference to drug code 7360 

(Marihuana), the company plans to bulk 

manufacture cannabidiol as a synthetic 

intermediate. This controlled substance 

will be further synthesized to bulk 

manufacture a synthetic THC (7370). No 

other activity for this drug code is 

authorized for this registration. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

AMRI Rensselaer, Inc. to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated AMRI Rensselaer, Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: September 22, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–22876 Filed 9–26–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated June 3, 2008 and 

published in the Federal Register on 

June 10, 2008 (73 FR 32736), Cambrex 

Charles City, Inc., 1205 11th Street, 

Charles City, Iowa 50616, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of 

Phenylacetone (8501), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import 

Phenylacetone for use as a precursor in 

the manufacture of amphetamine only. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Cambrex Charles City, Inc. to import the 

basic class of controlled substance is 

consistent with the public interest, and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Cambrex Charles City, Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

mstockstill on PROD1PC66 with NOTICES